MedTrace Logo

Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544

NCT07563894 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-05-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the relative bioavailability (rBA) of the Form 2 film-coated tablet of PF-07799933 intended for use in future studies compared to the current Form 1 tablet of PF-07799933 used in Phase 1 studies. Additionally this study will also evaluate the effect of a high-fat meal on the plasma pharmacokinetics (PK), i.e, the rBA compared to overnight fasting, of PF-07799933 and PF-07799544 following concurrent single-dose oral administration of Form 2 film-coated tablet formulation of PF-07799933 with PF-07799544. Finally, this study will also assess the impact of a proton pump inhibitor (a type of acid reducing agent) on PF-07799933 PK of the Form 2 film-coated tablet formulation. These data will be used to inform administration of PF-07799933 and PF-07799544 with food and acid reducing agents in future clinical trials.

Conditions

  • Healthy

Interventions

DRUG

PF-07799933 tablets with PF-07799544 fasted

Participants receive Form 1 in a single dose of tablet in a single dose combination fasted

DRUG

PF-07799933 film-coated tablets with PF-07799544 fasted

Participants receive Form 2 in a single dose of tablet in a single dose combination fasted

DRUG

PF-07799933 film-coated tablets with PF-07799544 fed

Participants receive Form 2 in a single dose of tablet in a single dose combination in the fed state

DRUG

PF-07799933 film-coated tablets fasted

Participants receive Form 2 in a single dose of tablet fasted

DRUG

PF-07799933 film-coated tablets following rabeprazole pretreatment fasted

Participants receive Form 2 in a single dose of tablet following rabeprazole pre-treatment fasted

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-10
Primary Completion
2026-06-24
Completion
2026-06-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07563894 on ClinicalTrials.gov